BRPI0607792A2 - processo para a preparação de moduladores de opióides - Google Patents

processo para a preparação de moduladores de opióides

Info

Publication number
BRPI0607792A2
BRPI0607792A2 BRPI0607792-7A BRPI0607792A BRPI0607792A2 BR PI0607792 A2 BRPI0607792 A2 BR PI0607792A2 BR PI0607792 A BRPI0607792 A BR PI0607792A BR PI0607792 A2 BRPI0607792 A2 BR PI0607792A2
Authority
BR
Brazil
Prior art keywords
preparation
opioid modulators
modulators
opioid
agonists
Prior art date
Application number
BRPI0607792-7A
Other languages
English (en)
Inventor
Chaozhong Cai
Wei He
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36646011&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607792(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0607792A2 publication Critical patent/BRPI0607792A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROCESSO PARA A PREPARAçãO DE MODULADORES DE OPIóIDES. A presente invenção refere-se para os novos processos para a preparação de moduladores de opióides (agonistas e antagonistas) e intermediários na síntese dos mesmos., Os moduladores de opióides são úteis para o tratamento e a prevenção de dores e distúrbios gastrointestinais.
BRPI0607792-7A 2005-03-14 2006-03-06 processo para a preparação de moduladores de opióides BRPI0607792A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66178405P 2005-03-14 2005-03-14
PCT/US2006/008240 WO2006098982A1 (en) 2005-03-14 2006-03-06 Process for the preparation of opioid modulators

Publications (1)

Publication Number Publication Date
BRPI0607792A2 true BRPI0607792A2 (pt) 2009-06-13

Family

ID=36646011

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0607793-5A BRPI0607793A2 (pt) 2005-03-14 2006-03-06 processo para a preparação de moduladores opióides
BRPI0607792-7A BRPI0607792A2 (pt) 2005-03-14 2006-03-06 processo para a preparação de moduladores de opióides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0607793-5A BRPI0607793A2 (pt) 2005-03-14 2006-03-06 processo para a preparação de moduladores opióides

Country Status (30)

Country Link
US (4) US7629488B2 (pt)
EP (2) EP1863764A1 (pt)
JP (3) JP5384933B2 (pt)
KR (2) KR101280929B1 (pt)
CN (2) CN101175726A (pt)
AR (2) AR054745A1 (pt)
AU (2) AU2006223482A1 (pt)
BR (2) BRPI0607793A2 (pt)
CA (2) CA2601481C (pt)
CR (1) CR9438A (pt)
CY (1) CY1116104T1 (pt)
DK (1) DK1858850T3 (pt)
EA (2) EA014366B1 (pt)
ES (1) ES2535048T3 (pt)
HR (1) HRP20150417T1 (pt)
HU (1) HUE024912T2 (pt)
IL (3) IL185972A (pt)
ME (1) ME02110B (pt)
MX (2) MX2007011412A (pt)
MY (1) MY145333A (pt)
NI (1) NI200700237A (pt)
NO (2) NO340604B1 (pt)
NZ (1) NZ590570A (pt)
PL (1) PL1858850T3 (pt)
PT (1) PT1858850E (pt)
RS (1) RS53873B1 (pt)
SI (1) SI1858850T1 (pt)
TW (3) TWI500595B (pt)
WO (2) WO2006099060A2 (pt)
ZA (2) ZA200708809B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
TWI361069B (en) * 2004-03-15 2012-04-01 Janssen Pharmaceutica Nv Novel compounds as opioid receptor modulators
MX2007011412A (es) * 2005-03-14 2008-02-22 Johnson & Johnson Procedimiento para la preparacion de moduladores de opioide.
CN101730685A (zh) 2007-07-09 2010-06-09 詹森药业有限公司 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017043626A1 (ja) * 2015-09-11 2017-03-16 株式会社カネカ 光学活性４－カルバモイル－２，６－ジメチルフェニルアラニン誘導体の製造法
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
EP3474847B1 (en) * 2016-06-23 2022-09-07 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
EP3515434A4 (en) 2016-09-20 2020-02-26 Sun Pharmaceutical Industries Limited METHOD FOR PRODUCING ELUXADOLIN
CN106866463B (zh) * 2017-01-24 2018-08-28 富乐马鸿凯（大连）医药有限公司 艾沙度林中间体的制备方法
US10738013B2 (en) 2017-01-27 2020-08-11 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
WO2021201036A1 (ja) 2020-03-31 2021-10-07 田辺三菱製薬株式会社 ヒドロキシピロリジン誘導体およびその医薬用途
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法
CN114507252B (zh) * 2022-02-21 2023-10-27 广西大学 新型芳基硅烷化合物的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5430129A (en) * 1977-08-09 1979-03-06 Mitsubishi Gas Chem Co Inc Preparation of toluic acid amide
JPS5528959A (en) * 1978-08-22 1980-02-29 Sumitomo Chem Co Ltd Production of amide derivative
FR2584401B1 (fr) * 1985-07-04 1987-11-20 Ile De France Nouveau benzamide, son procede de preparation et son application dans le domaine therapeutique
JP2727243B2 (ja) * 1988-12-27 1998-03-11 日本化薬株式会社 ２−アシルアミノ桂皮酸誘導体の製造法
US5684175A (en) * 1993-02-05 1997-11-04 Napro Biotherapeutics, Inc. C-2' hydroxyl-benzyl protected, N-carbamate protected (2R, 3S)- 3-phenylisoserine and production process therefor
JP3493206B2 (ja) * 1993-03-19 2004-02-03 ダイセル化学工業株式会社 光学活性β−アミノ酸類の製法
JP3486922B2 (ja) * 1993-08-23 2004-01-13 住友化学工業株式会社 酸アミドの製造法
EP0805816B1 (en) * 1995-01-27 2004-07-28 Novo Nordisk A/S Compounds with growth hormone releasing properties
JPH09295939A (ja) * 1995-09-26 1997-11-18 Takeda Chem Ind Ltd リン酸アミド誘導体、その製造法および用途
GEP20043179B (en) * 1998-03-11 2004-02-25 Searle & Co Halogenated Amidino Amino Acid Derivatives Useful as Nitric Oxide Synthase Inhibitors
EP1055665B1 (en) * 1999-05-28 2003-10-22 Pfizer Products Inc. 3-(3-Hydroxyphenyl)-3-amino-propionamide derivatives
CA2422617C (en) * 2000-10-30 2011-07-12 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
TWI361069B (en) * 2004-03-15 2012-04-01 Janssen Pharmaceutica Nv Novel compounds as opioid receptor modulators
MX2007011412A (es) * 2005-03-14 2008-02-22 Johnson & Johnson Procedimiento para la preparacion de moduladores de opioide.

Also Published As

Publication number Publication date
PL1858850T3 (pl) 2015-06-30
IL209402A0 (en) 2011-01-31
ZA200708810B (en) 2009-01-28
JP2013234192A (ja) 2013-11-21
WO2006099060A3 (en) 2006-11-02
CY1116104T1 (el) 2017-02-08
US20100036132A1 (en) 2010-02-11
SI1858850T1 (sl) 2015-04-30
CN101175725A (zh) 2008-05-07
CN101175726A (zh) 2008-05-07
KR101280929B1 (ko) 2013-07-01
NO340604B1 (no) 2017-05-15
EA015512B1 (ru) 2011-08-30
CA2601481C (en) 2013-11-12
JP5802242B2 (ja) 2015-10-28
JP2008533141A (ja) 2008-08-21
KR20070116067A (ko) 2007-12-06
ME02110B (me) 2015-10-20
ZA200708809B (en) 2009-03-25
US20060211863A1 (en) 2006-09-21
EP1863764A1 (en) 2007-12-12
MX2007011412A (es) 2008-02-22
CA2601481A1 (en) 2006-09-21
AU2006223394A1 (en) 2006-09-21
ES2535048T3 (es) 2015-05-04
PT1858850E (pt) 2015-02-24
AR054745A1 (es) 2007-07-11
US20060211861A1 (en) 2006-09-21
TW201302676A (zh) 2013-01-16
EP1858850A2 (en) 2007-11-28
NZ590570A (en) 2012-06-29
CR9438A (es) 2008-09-09
US7629488B2 (en) 2009-12-08
MY145333A (en) 2012-01-31
MX2007011409A (es) 2008-02-22
CA2601674A1 (en) 2006-09-21
WO2006098982A1 (en) 2006-09-21
TW200716548A (en) 2007-05-01
TWI414518B (zh) 2013-11-11
TW200700388A (en) 2007-01-01
KR20070112255A (ko) 2007-11-22
AU2006223482A1 (en) 2006-09-21
DK1858850T3 (en) 2015-02-09
NI200700237A (es) 2008-06-25
IL209402A (en) 2015-06-30
TWI500595B (zh) 2015-09-21
NO20075268L (no) 2007-12-10
JP2008533143A (ja) 2008-08-21
RS53873B1 (en) 2015-08-31
BRPI0607793A2 (pt) 2009-06-13
JP5384933B2 (ja) 2014-01-08
HUE024912T2 (en) 2016-02-29
EA200701979A1 (ru) 2008-04-28
IL185972A0 (en) 2008-01-06
EP1858850B1 (en) 2015-01-21
NO20075269L (no) 2007-12-10
EA014366B1 (ru) 2010-10-29
IL185974A0 (en) 2008-01-06
AR053170A1 (es) 2007-04-25
US20100152460A1 (en) 2010-06-17
CN101175725B (zh) 2011-02-02
EA200701978A1 (ru) 2008-04-28
IL185972A (en) 2013-07-31
HRP20150417T1 (en) 2015-09-25
WO2006099060A2 (en) 2006-09-21
AU2006223394B2 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
BRPI0607792A2 (pt) processo para a preparação de moduladores de opióides
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0906064A2 (pt) "peptídeo, processo para obtenção de um peptídeo de fórmula geral (i), composição cosmética ou farmacêutica e uso de um peptídeo de fórmula geral (i)"
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
BRPI0922381A2 (pt) "processo para síntese de di-ou oligossacarídeos de l-fucose e novos derivados intermediários de 2,3,4-tribenzil-fucose dos mesmos."
GB0524814D0 (en) Compounds
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
BRPI0514111B8 (pt) derivados de benzamidina, processo para a preparação destes e composição farmacêutica compreendendo os mesmos
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
BRPI0818813A2 (pt) Compostos derivados de metil-benzimidazol, processo para a manufatura desses compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ ou profilático de enfermidades que são afetadas por moduladores de fxr e uso de tais compostos
CL2011001122A1 (es) Compuestos derivados de carbamatos de alquilheterociclos; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir o tratar dolores agudos o cronicos, patologias neurologicas y psiquiatricas, enfermedades cardiovasculares, entre otras.
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
BRPI0605902A (pt) processo de purificação para intermediário de anastrozol
PL1778622T3 (pl) Para-alkilo-podstawione amidy kwasu N-(hydroksy-3-metoksybenzylo)-cynamonowego i ich zastosowanie do wytwarzania środków leczniczych
BRPI0911159A2 (pt) compostos derivados de ácido 4-dimetilaminobutírico, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico ou profilático de enfermidades que são moduladas por inibidres de cpt2 e uso destes compostos
EA200970355A1 (ru) Новый кристалл (s)-(+)-2-(2-хлорфенил)-2-гидроксиэтилкарбамата
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
HK1128462A1 (en) Novel method for preparation of ammonium salts of esomeprazole
WO2006074873A3 (en) New one-step synthesis of useful disubstituted amines

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.